(19)
(11) EP 1 943 251 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
23.03.2011 Bulletin 2011/12

(45) Mention of the grant of the patent:
09.02.2011 Bulletin 2011/06

(21) Application number: 06825861.5

(22) Date of filing: 11.10.2006
(51) International Patent Classification (IPC): 
C07D 473/00(2006.01)
A61K 31/52(2006.01)
A61P 3/10(2006.01)
 C07H 19/16(2006.01)
A61P 9/06(2006.01)
A61P 25/00(2006.01)
(86) International application number:
PCT/US2006/039975
(87) International publication number:
WO 2007/047401 (26.04.2007 Gazette 2007/17)

(54)

A1 ADENOSINE RECEPTOR AGONISTS

A1-ADENOSINREZEPTORAGONISTEN

AGONISTES DU RÉCEPTEUR A1 DE L'ADÉNOSINE

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR
Designated Extension States:
AL BA HR MK RS

(30) Priority: 13.10.2005 US 726616 P

(43) Date of publication of application:
16.07.2008 Bulletin 2008/29

(73) Proprietor: Gilead Palo Alto, Inc.
Foster City, CA 94404 (US)

(72) Inventors:
  • ELZEIN, Elfatih
    Fremont, CA 94555 (US)
  • LI, Xiaofen
    Mountain View, CA 94040 (US)
  • ZABLOCKI, Jeff
    Los Altos, CA 94022 (US)

(74) Representative: Schnappauf, Georg et al
Dr. Volker Vossius Patent- und Rechtsanwaltskanzlei Geibelstrasse 6
81679 München
81679 München (DE)


(56) References cited: : 
WO-A-00/23457
WO-A-03/014137
 WO-A-02/094273
WO-A-2004/069185
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).